Provided by Tiger Trade Technology Pte. Ltd.

Day One Biopharmaceuticals Inc.

11.41
+0.93008.87%
Post-market: 11.410.00000.00%19:49 EST
Volume:3.13M
Turnover:35.41M
Market Cap:1.17B
PE:-7.74
High:11.50
Open:11.06
Low:10.84
Close:10.48
52wk High:13.20
52wk Low:5.64
Shares:102.68M
Float Shares:78.77M
Volume Ratio:1.61
T/O Rate:3.97%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4748
EPS(LYR):-1.0243
ROE:-30.16%
ROA:-18.57%
PB:2.60
PE(LYR):-11.14

Loading ...

'Follow The Money,' Not The Tariff Noise, Says Expert, Spotlights This New S&P Data Center Cooling Stock Among Top Picks

Benzinga_recent_news
·
Jan 21

Day One Biopharmaceuticals reinstated with a Buy at TD Cowen

TIPRANKS
·
Jan 13

Day One Biopharmaceuticals: Ojemda Outperformance and Advancing Pipeline Support Overweight Rating

TIPRANKS
·
Jan 13

Day One Biopharmaceuticals Inc : TD Cowen Reinstates Coverage With Buy Rating; Target Price $34

THOMSON REUTERS
·
Jan 13

A Look At Day One Biopharmaceuticals (DAWN) Valuation After Strong OJEMDA Revenue Update And 2026 Sales Guidance

Simply Wall St.
·
Jan 13

Day One Biopharma Shares Rise on Ojemda Sales Outlook

Dow Jones
·
Jan 12

Day One reports preliminary FY25 Ojemda net product revenue of $155.4M

TIPRANKS
·
Jan 12

Day One Biopharmaceuticals Projects 2026 OJEMDA Revenue of $225–$250 Million

Reuters
·
Jan 12

Day One Announces Preliminary 2025 Ojemda™ Net Product Revenue and Provides 2026 Net Product Revenue Guidance

THOMSON REUTERS
·
Jan 12

Mersana Therapeutics Shareholders to Receive $25 Per Share in Acquisition by Day One Biopharmaceuticals

Reuters
·
Jan 06

Day One Biopharmaceuticals CEO to Present at J.P. Morgan Healthcare Conference

Reuters
·
Dec 16, 2025

Buy Rating Affirmed for Day One Biopharmaceuticals Based on Promising Long-Term Data from FIREFLY-1 Trial

TIPRANKS
·
Nov 25, 2025

Day One Biopharmaceuticals Reveals Promising Phase 2 Trial Results

TIPRANKS
·
Nov 25, 2025

Day One Biopharm Price Target Maintained With a $16.00/Share by Needham

Dow Jones
·
Nov 24, 2025

Day One Biopharmaceuticals Reports Three-Year Data Showing Durable Responses for OJEMDA in Pediatric Low-Grade Glioma

Reuters
·
Nov 24, 2025

Day One Announces Three Year Follow-up Data From Ojemda™ (Tovorafenib) Phase 2 Firefly-1 Trial at the 2025 Society for Neuro-Oncology (Sno) Annual Meeting

THOMSON REUTERS
·
Nov 24, 2025

Press Release: Day One Announces Three Year Follow-Up Data From OJEMDA(TM) (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting

Dow Jones
·
Nov 24, 2025

BUZZ-Nasdaq biotech index hits record high, set to gain nearly 5% this week

Reuters
·
Nov 15, 2025

Mersana Therapeutics reports third quarter 2025 financial results

Reuters
·
Nov 14, 2025

Sector Update: Health Care Stocks Edge Higher Late Afternoon

MT Newswires Live
·
Nov 14, 2025